Efficacy and safety of secukinumab, a fully human anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriatic arthritis: a 24-week, randomised, double-blind, placebo-controlled, phase II proof-of-concept trial

✍ Scribed by McInnes, I. B.; Sieper, J.; Braun, J.; Emery, P.; van der Heijde, D.; Isaacs, J. D.; Dahmen, G.; Wollenhaupt, J.; Schulze-Koops, H.; Kogan, J.; Ma, S.; Schumacher, M. M.; Bertolino, A. P.; Hueber, W.; Tak, P. P.

• Book ID: 121355073
• Publisher: BMJ Publishing Group
• Year: 2013
• Tongue: English
• Weight: 471 KB
• Volume: 73
• Category: Article
• ISSN: 0003-4967
• DOI: 10.1136/annrheumdis-2012-202646